Zydus Lifesciences Gets Final U.S.FDA Nod To Manufacture, Market Ulcer Drug

The approval granted by the U.S. Food and Drug Administration is to manufacture and market Sucralfate Tablets of strength 1 gram, Zydus Lifesciences said in a regulatory filing.

The drug will be manufactured at the group’s topical manufacturing facility at SEZ, Ahmedabad, it added.

Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury, and thus helps ulcers heal more quickly, the company said.

Sucralfate tablets 1 gram had annual sales of $84 million in the U.S., it said citing IQVIA MAT February 2023 data.